Ensysce Biosciences Inc (ENSC)

$2.25 -0.08 (-3.43%)
Market Cap 6.92M
Revenue (ttm) 5.21M
Net Income (ttm) -7.99M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -153.36%
Debt to Equity Ratio 0.00
Volume 104,500
Avg Vol 129,626
Day's Range N/A - N/A
Shares Out 2.97M
Stochastic %K 7%
Beta 1.10
Analysts Strong Buy
Price Target $18.45

Company Profile

Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, develops prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, designed to release clinically effective drugs only when exposed to specific physiological conditions; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology. The company's lead product candidate is...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 263 4196
Address:
7946 Ivanhoe Avenue, Suite 201, La Jolla, United States
Risingilluminati
Risingilluminati Oct. 11 at 5:14 AM
I found a stock that is super undervalued and a beaten down gem. Check out VRME🚨🚀 Make sure to put VRME on ur watchlist! I think wehn more folks finds this can have a massive run. VRME - VerifyMe, Inc. 🔹Crypto Treasury Strategy PR Buzz--(This could be massive)!!🚨 🔹Enters into a UPS Digital Channel Program Agreement with United Parcel Service, Inc and UPS Worldwide Forwarding, Inc 🔹The Agreements provide Periship access to designated UPS services at promotional rates for a 3 year term 🔹Low float/ OS near 12.5m shares 🔹Strong cash position of $6.1 Million $ADN $ENSC $RADX $KRKR ...
0 · Reply
JdlawVT40
JdlawVT40 Oct. 11 at 3:28 AM
$ENSC have held this stock for many moons. love the story and the science. Of course, no profit yet, but I’m optimistic. Also have other bios, most urgently SLS which in my opinion will be a huge winner.
0 · Reply
ttesty
ttesty Oct. 10 at 11:27 PM
$ENSC gonna get crushed by $ARTL.
1 · Reply
Mateine
Mateine Oct. 10 at 12:14 PM
$ENSC https://ir.ensysce.com/news/press-releases/detail/200/ensysce-biosciences-releases-symposium-highlights-from
0 · Reply
BULLISH1975
BULLISH1975 Oct. 10 at 12:53 AM
$ENSC i think the big instos will be adding / buying this year! these huge grants definitely help with funding! this science looks rock solid. i think many drugs could benefit from this science! will big pharma want access to this science??? likely imo
0 · Reply
BULLISH1975
BULLISH1975 Oct. 10 at 12:50 AM
$ENSC ‘TAAP™ can provide improved drug performance. Ensysce’s TAAP™ prodrugs can potentially improve attributes of other FDA-approved drugs, through enhanced bioavailability, controlled duration of action, improved safety, increased solubility and reducing susceptibility to abuse. MPAR® can switch off the activation of TAAP™ products. MPAR provides another layer of protection and safety to Ensysce’s TAAP™ prodrugs. Composition-of-matter patent protection. All TAAP™ and MPAR® drug products are protected through Composition-of-matter patent protection. TAAP™ applied to other approved therapies produces new composition of matter and provides a strategy for life cycle management.’ lots of opportunities to partner …
0 · Reply
BULLISH1975
BULLISH1975 Oct. 10 at 12:48 AM
$ENSC ‘FDA guidance. Given the growing desire of multiple federal agencies – including the FDA – to transition to more abuse-resistant products, Ensysce’s innovative solutions are set to establish us as a market-leading player and partner in an increasingly competitive landscape.’ partner…💰💰💰💰
1 · Reply
BULLISH1975
BULLISH1975 Oct. 9 at 6:43 PM
$ENSC too much potential here to not add a few! its been a horrible stock for years but it seems to have stabilized. They have over 15 million in grants- double the current MC. the Science has delivered great results for years with no SP appreciation. very good chance these drugs will get approved IMO! there is an oxycodone crisis! the world and people in pain need this product IMO. float is small so the big money could pump it over $20 quickly ! got a few now for the long haul. 🤞🤞🤞dyor
0 · Reply
Here2trollBullz
Here2trollBullz Oct. 9 at 6:07 AM
$ENSC mj fade away incoming🏀 92 bulls version😂🤝
1 · Reply
Kingcrab3333
Kingcrab3333 Oct. 8 at 9:45 PM
$ENSC Soon
0 · Reply
Latest News on ENSC
Ensysce Biosciences Releases Symposium Highlights from PAINWeek 2025

Oct 10, 2025, 8:00 AM EDT - 1 day ago

Ensysce Biosciences Releases Symposium Highlights from PAINWeek 2025

Ensysce Biosciences Showcases Urgent Need for Safer Opioids at PAINWeek 2025 Symposium

Sep 4, 2025, 8:00 AM EDT - 5 weeks ago

Ensysce Biosciences Showcases Urgent Need for Safer Opioids at PAINWeek 2025 Symposium

Ensysce Biosciences' Geoff Birkett to Chair the Fierce New Product Planning Summit 2025

Aug 19, 2025, 8:00 AM EDT - 7 weeks ago

Ensysce Biosciences' Geoff Birkett to Chair the Fierce New Product Planning Summit 2025

Diamond Equity Research Releases Update Note on Ensysce Biosciences, Inc. (NASDAQ: ENSC)

Aug 15, 2025, 8:00 AM EDT - 2 months ago

Diamond Equity Research Releases Update Note on Ensysce Biosciences, Inc. (NASDAQ: ENSC)

Ensysce Biosciences Reports Second Quarter 2025 Financial Results and Latest Program Updates

Aug 13, 2025, 4:15 PM EDT - 2 months ago

Ensysce Biosciences Reports Second Quarter 2025 Financial Results and Latest Program Updates

Ensysce Biosciences Advances Breakthrough Opioid With Built-In Overdose Protection Following Positive FDA Feedback

Jul 31, 2025, 8:00 AM EDT - 2 months ago

Ensysce Biosciences Advances Breakthrough Opioid With Built-In Overdose Protection Following Positive FDA Feedback

Ensysce Biosciences Initiates Pivotal Phase 3 Study of PF614 - A Next-Generation Opioid - Designed to Deliver Powerful Pain Relief and Reduce Abuse

Jul 16, 2025, 8:00 AM EDT - 3 months ago

Ensysce Biosciences Initiates Pivotal Phase 3 Study of PF614 - A Next-Generation Opioid - Designed to Deliver Powerful Pain Relief and Reduce Abuse

Ensysce Biosciences Accelerates PF614-MPAR-102 Study with Full Enrollment of Part 2

Jun 24, 2025, 8:00 AM EDT - 3 months ago

Ensysce Biosciences Accelerates PF614-MPAR-102 Study with Full Enrollment of Part 2

Ensysce Biosciences Announces Speakers for Major Symposium at PAINWeek 2025

Jun 11, 2025, 8:00 AM EDT - 4 months ago

Ensysce Biosciences Announces Speakers for Major Symposium at PAINWeek 2025

Ensysce Biosciences Awarded $5.3 Million in Continued NIDA Support to Advance Breakthrough Opioid Overdose Protection

Jun 4, 2025, 8:00 AM EDT - 4 months ago

Ensysce Biosciences Awarded $5.3 Million in Continued NIDA Support to Advance Breakthrough Opioid Overdose Protection

Ensysce Biosciences Reports First Quarter 2025 Financial Results

May 13, 2025, 4:15 PM EDT - 5 months ago

Ensysce Biosciences Reports First Quarter 2025 Financial Results

Ensysce Biosciences Bolsters Management Team with Regulatory Expert

May 12, 2025, 8:00 AM EDT - 5 months ago

Ensysce Biosciences Bolsters Management Team with Regulatory Expert

Ensysce Biosciences, Inc. Announces Closing of Exercise of Warrants for $2.2 Million Gross Proceeds

Apr 24, 2025, 4:15 PM EDT - 6 months ago

Ensysce Biosciences, Inc. Announces Closing of Exercise of Warrants for $2.2 Million Gross Proceeds

Ensysce Biosciences Stock Doubles In One Trading Session - Here's Why

Apr 23, 2025, 5:11 PM EDT - 6 months ago

Ensysce Biosciences Stock Doubles In One Trading Session - Here's Why

Ensysce Biosciences, Inc. Announces Exercise of Warrants for $2.2 Million Gross Proceeds

Apr 23, 2025, 4:41 PM EDT - 6 months ago

Ensysce Biosciences, Inc. Announces Exercise of Warrants for $2.2 Million Gross Proceeds

Ensysce Biosciences Receives U.S. Patent for Groundbreaking Treatment of Opioid Use Disorder

Apr 23, 2025, 8:00 AM EDT - 6 months ago

Ensysce Biosciences Receives U.S. Patent for Groundbreaking Treatment of Opioid Use Disorder

Ensysce Biosciences Announces Positive Data from Opioid Overdose Protection Study

Apr 15, 2025, 8:00 AM EDT - 6 months ago

Ensysce Biosciences Announces Positive Data from Opioid Overdose Protection Study

Ensysce Biosciences, Inc. Announces $1.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Mar 31, 2025, 8:00 AM EDT - 6 months ago

Ensysce Biosciences, Inc. Announces $1.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Ensysce Biosciences Announces PAINWeek 2025 Symposium and Recent Expert Panel Discussion on The State of the Nation in Pain

Mar 18, 2025, 8:00 AM EDT - 7 months ago

Ensysce Biosciences Announces PAINWeek 2025 Symposium and Recent Expert Panel Discussion on The State of the Nation in Pain

Ensysce Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results

Mar 10, 2025, 4:15 PM EDT - 7 months ago

Ensysce Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results

Ensysce Biosciences to Participate in the 37th Annual ROTH Conference

Mar 5, 2025, 8:00 AM EST - 7 months ago

Ensysce Biosciences to Participate in the 37th Annual ROTH Conference

Ensysce Biosciences CEO Dr. Lynn Kirkpatrick and Creighton University's Dr. Neel Pathak Discuss the Opioid Crisis and Next Generation Opioids

Mar 3, 2025, 9:43 AM EST - 7 months ago

Ensysce Biosciences CEO Dr. Lynn Kirkpatrick and Creighton University's Dr. Neel Pathak Discuss the Opioid Crisis and Next Generation Opioids

Ensysce Biosciences Reports Continued Positive Progress in Groundbreaking Trial on PF614-MPAR, Comments on Current Landscape for Pain Treatment

Feb 5, 2025, 8:00 AM EST - 8 months ago

Ensysce Biosciences Reports Continued Positive Progress in Groundbreaking Trial on PF614-MPAR, Comments on Current Landscape for Pain Treatment

Ensysce Biosciences Announces Positive Interim Data for Breakthrough Therapy PF614-MPAR

Jan 22, 2025, 8:00 AM EST - 9 months ago

Ensysce Biosciences Announces Positive Interim Data for Breakthrough Therapy PF614-MPAR

Ensysce Biosciences Issues Annual Shareholder Letter

Jan 8, 2025, 8:00 AM EST - 9 months ago

Ensysce Biosciences Issues Annual Shareholder Letter

Ensysce Biosciences Regains Full Compliance with Nasdaq

Dec 23, 2024, 8:00 AM EST - 10 months ago

Ensysce Biosciences Regains Full Compliance with Nasdaq

Ensysce Biosciences Announces Commercial Supplier for Breakthrough Overdose Protection Drug Product

Dec 10, 2024, 8:00 AM EST - 10 months ago

Ensysce Biosciences Announces Commercial Supplier for Breakthrough Overdose Protection Drug Product

Ensysce Biosciences Announces Strategic Partnership for the Development and Commercial Launch of PF614 and PF614-MPAR

Dec 4, 2024, 8:00 AM EST - 11 months ago

Ensysce Biosciences Announces Strategic Partnership for the Development and Commercial Launch of PF614 and PF614-MPAR

Ensysce Biosciences Announces 1-for-15 Reverse Stock Split

Dec 3, 2024, 4:15 PM EST - 11 months ago

Ensysce Biosciences Announces 1-for-15 Reverse Stock Split

Ensysce Biosciences Completes Significant Milestone, Dosing First Subjects in Breakthrough Therapy PF614-MPAR Trial

Nov 26, 2024, 8:00 AM EST - 11 months ago

Ensysce Biosciences Completes Significant Milestone, Dosing First Subjects in Breakthrough Therapy PF614-MPAR Trial

Ensysce Biosciences Reports Third Quarter 2024 Financial Results

Nov 12, 2024, 4:15 PM EST - 11 months ago

Ensysce Biosciences Reports Third Quarter 2024 Financial Results

Ensysce Biosciences Receives Positive Nasdaq Listing Determination

Nov 7, 2024, 8:00 AM EST - 1 year ago

Ensysce Biosciences Receives Positive Nasdaq Listing Determination

Ensysce Biosciences Announces Leadership Team's Participation in the Annual Pain Therapeutics Summit

Oct 8, 2024, 8:00 AM EDT - 1 year ago

Ensysce Biosciences Announces Leadership Team's Participation in the Annual Pain Therapeutics Summit

Ensysce Biosciences Provides Shareholder Update, Responds to Recent Shareholder Inquiries

Oct 2, 2024, 8:00 AM EDT - 1 year ago

Ensysce Biosciences Provides Shareholder Update, Responds to Recent Shareholder Inquiries

Ensysce Biosciences Receives Notice from Nasdaq

Sep 27, 2024, 4:30 PM EDT - 1 year ago

Ensysce Biosciences Receives Notice from Nasdaq

Ensysce Biosciences Presenting at Upcoming Meetings

Sep 24, 2024, 8:00 AM EDT - 1 year ago

Ensysce Biosciences Presenting at Upcoming Meetings

Ensysce Biosciences Submits Phase 3 Protocol to the FDA

Sep 19, 2024, 7:00 AM EDT - 1 year ago

Ensysce Biosciences Submits Phase 3 Protocol to the FDA

Ensysce Biosciences Posts Video Updates from the IASP World Congress on Pain 2024

Sep 13, 2024, 8:00 AM EDT - 1 year ago

Ensysce Biosciences Posts Video Updates from the IASP World Congress on Pain 2024

Ensysce Biosciences, Inc. Announces $5 Million Concurrent Registered Direct Offering and Exercise of Warrants

Aug 29, 2024, 8:00 AM EDT - 1 year ago

Ensysce Biosciences, Inc. Announces $5 Million Concurrent Registered Direct Offering and Exercise of Warrants

Ensysce Biosciences Announces IRB Approval for Key MPAR Study

Aug 27, 2024, 2:30 PM EDT - 1 year ago

Ensysce Biosciences Announces IRB Approval for Key MPAR Study

Ensysce Biosciences Receives $14 Million NIH Grant for Clinical Development of Novel Opioid with Overdose Protection

Aug 27, 2024, 8:00 AM EDT - 1 year ago

Ensysce Biosciences Receives $14 Million NIH Grant for Clinical Development of Novel Opioid with Overdose Protection

Ensysce Biosciences Reports Second Quarter 2024 Financial Results

Aug 14, 2024, 4:15 PM EDT - 1 year ago

Ensysce Biosciences Reports Second Quarter 2024 Financial Results

Ensysce Biosciences Provides Key Themes Following IASP 2024 Symposium

Aug 8, 2024, 8:25 AM EDT - 1 year ago

Ensysce Biosciences Provides Key Themes Following IASP 2024 Symposium

Ensysce Biosciences Provides Mid-Year 2024 Update

Jul 23, 2024, 8:00 AM EDT - 1 year ago

Ensysce Biosciences Provides Mid-Year 2024 Update

Ensysce Biosciences Hosts IASP 2024 Symposium and Presents Clinical Dataset

Jul 9, 2024, 8:00 AM EDT - 1 year ago

Ensysce Biosciences Hosts IASP 2024 Symposium and Presents Clinical Dataset

Ensysce Biosciences Discusses Key Themes from the EPHMRA 2024 Annual Meeting

Jun 27, 2024, 8:00 AM EDT - 1 year ago

Ensysce Biosciences Discusses Key Themes from the EPHMRA 2024 Annual Meeting

Ensysce Biosciences Announces Partnership to Scale and Manufacture New Drug Candidate

Jun 25, 2024, 8:00 AM EDT - 1 year ago

Ensysce Biosciences Announces Partnership to Scale and Manufacture New Drug Candidate

Ensysce Biosciences Announces Major Milestone for Opioid Use Disorder Program

Jun 6, 2024, 8:00 AM EDT - 1 year ago

Ensysce Biosciences Announces Major Milestone for Opioid Use Disorder Program

Ensysce Biosciences to Participate in the EPHMRA 2024 Annual Meeting

Jun 3, 2024, 8:00 AM EDT - 1 year ago

Ensysce Biosciences to Participate in the EPHMRA 2024 Annual Meeting

Ensysce Biosciences Continues Collaboration to Advance the Clinical Development of Innovative Overdose Protection Platform

May 20, 2024, 8:00 AM EDT - 1 year ago

Ensysce Biosciences Continues Collaboration to Advance the Clinical Development of Innovative Overdose Protection Platform

Risingilluminati
Risingilluminati Oct. 11 at 5:14 AM
I found a stock that is super undervalued and a beaten down gem. Check out VRME🚨🚀 Make sure to put VRME on ur watchlist! I think wehn more folks finds this can have a massive run. VRME - VerifyMe, Inc. 🔹Crypto Treasury Strategy PR Buzz--(This could be massive)!!🚨 🔹Enters into a UPS Digital Channel Program Agreement with United Parcel Service, Inc and UPS Worldwide Forwarding, Inc 🔹The Agreements provide Periship access to designated UPS services at promotional rates for a 3 year term 🔹Low float/ OS near 12.5m shares 🔹Strong cash position of $6.1 Million $ADN $ENSC $RADX $KRKR ...
0 · Reply
JdlawVT40
JdlawVT40 Oct. 11 at 3:28 AM
$ENSC have held this stock for many moons. love the story and the science. Of course, no profit yet, but I’m optimistic. Also have other bios, most urgently SLS which in my opinion will be a huge winner.
0 · Reply
ttesty
ttesty Oct. 10 at 11:27 PM
$ENSC gonna get crushed by $ARTL.
1 · Reply
Mateine
Mateine Oct. 10 at 12:14 PM
$ENSC https://ir.ensysce.com/news/press-releases/detail/200/ensysce-biosciences-releases-symposium-highlights-from
0 · Reply
BULLISH1975
BULLISH1975 Oct. 10 at 12:53 AM
$ENSC i think the big instos will be adding / buying this year! these huge grants definitely help with funding! this science looks rock solid. i think many drugs could benefit from this science! will big pharma want access to this science??? likely imo
0 · Reply
BULLISH1975
BULLISH1975 Oct. 10 at 12:50 AM
$ENSC ‘TAAP™ can provide improved drug performance. Ensysce’s TAAP™ prodrugs can potentially improve attributes of other FDA-approved drugs, through enhanced bioavailability, controlled duration of action, improved safety, increased solubility and reducing susceptibility to abuse. MPAR® can switch off the activation of TAAP™ products. MPAR provides another layer of protection and safety to Ensysce’s TAAP™ prodrugs. Composition-of-matter patent protection. All TAAP™ and MPAR® drug products are protected through Composition-of-matter patent protection. TAAP™ applied to other approved therapies produces new composition of matter and provides a strategy for life cycle management.’ lots of opportunities to partner …
0 · Reply
BULLISH1975
BULLISH1975 Oct. 10 at 12:48 AM
$ENSC ‘FDA guidance. Given the growing desire of multiple federal agencies – including the FDA – to transition to more abuse-resistant products, Ensysce’s innovative solutions are set to establish us as a market-leading player and partner in an increasingly competitive landscape.’ partner…💰💰💰💰
1 · Reply
BULLISH1975
BULLISH1975 Oct. 9 at 6:43 PM
$ENSC too much potential here to not add a few! its been a horrible stock for years but it seems to have stabilized. They have over 15 million in grants- double the current MC. the Science has delivered great results for years with no SP appreciation. very good chance these drugs will get approved IMO! there is an oxycodone crisis! the world and people in pain need this product IMO. float is small so the big money could pump it over $20 quickly ! got a few now for the long haul. 🤞🤞🤞dyor
0 · Reply
Here2trollBullz
Here2trollBullz Oct. 9 at 6:07 AM
$ENSC mj fade away incoming🏀 92 bulls version😂🤝
1 · Reply
Kingcrab3333
Kingcrab3333 Oct. 8 at 9:45 PM
$ENSC Soon
0 · Reply
Mateine
Mateine Oct. 8 at 8:38 PM
$ENSC wild day: 16K-share buy @ $2.82 early (from Robinhood), then dump to ~$2.37, then bounce back to ~$2.46. Volume ~ 869K — huge. Not interference — small float mechanics: 👉 big order sparks interest 👉 profit-taking + stops amplify drop 👉 bargain buyers push rebound Core still: fundamentals > intraday noise. DYOR.
0 · Reply
BULLISH1975
BULLISH1975 Oct. 8 at 6:08 PM
$ENSC 👀👀
0 · Reply
ttesty
ttesty Oct. 8 at 2:44 PM
$ENSC move like $AREB!!
0 · Reply
ourscooby
ourscooby Oct. 8 at 2:37 PM
$ENSC Don't forget to take your profits while you have them, before someone else does. Afterall that is literally the plan! This slow mover makes it easy for us. I've seen this happen too many times... then the boo birds come out :/ Then you can reposition for the future :)
1 · Reply
ttesty
ttesty Oct. 8 at 2:02 PM
$ENSC spikes to $3.2 back to $2.42. Need NEWS!
0 · Reply
CMT73
CMT73 Oct. 8 at 1:53 PM
$ENSC This is good…very good.
0 · Reply
shift_4
shift_4 Oct. 8 at 1:29 PM
$ENSC in case it isn't obvious, now they can license their TAAP feature to any new drug for a fee (new psychedelics, pain meds, etc.) because it'll improve the safety profile and reduce scheduling risk of the medication. And any company that doesn't jump on, they can just wait 20 years for their new molecule patent to expire and it go generic, and do it themselves and get 20 years of exclusivity that belongs to $ENSC. That's the trillion dollar future here. -$
1 · Reply
Love_To_Learn
Love_To_Learn Oct. 8 at 1:04 PM
$ENSC cautious off this 2.47* res check in this window
0 · Reply
Robol
Robol Oct. 8 at 12:22 PM
$ENSC
0 · Reply
FlyingKiteInvestingInc
FlyingKiteInvestingInc Oct. 8 at 12:20 PM
$ENVB $ENSC $APLT small penny bio pharm pumping this. Every day 300% all bio related penny stocks are momentum play!!!
1 · Reply
TruckMoney
TruckMoney Oct. 8 at 12:08 PM
$ENSC https://x.com/PatentAlerts4/status/1975892727448608816 $ENSC Ensysce Biosciences has received a Notice of Allowance for U.S. Patent Application No. 17/689,271 titled “Compositions Comprising Enzyme-Cleavable Prodrugs and Controlled Release Nafamostat and Methods of Use Thereof.”
0 · Reply
Mateine
Mateine Oct. 6 at 8:25 PM
$ENSC ENSC wild action today: ran to 2.64, then quick drop to 2.35, now back near 2.43. Not “mystery interference” — just small-cap mechanics: 👉 low float = big moves on small trades 👉 profit-taking after run-up 👉 stop-losses + shorts add pressure Long-term, it’s about fundamentals (Phase 3 start, FDA feedback, NIDA support) — not intraday swings. Stay focused. DYOR.
1 · Reply